Diamed Obesity S.R.L. — Clinical Trial Site

9 Registered trials

2 Currently recruiting

Organisation

Diamed Obesity S.R.L.

Location

Galati, Romania

Identifier

ORG-100042805

Address

Gheorghe Doja Nr 73, 800291, Romania

Departments

Diabet
Diabetes
Diabetes, Nutrition and Metabolic Diseases; Internal Medicine
Medicina Interna
N/A
NA
Private Practice, Diabetes and Cardiology
Societatea Diamed Obesity SRL

Clinical trials at this site (9)

Search interface

Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Hypertriglyceridemia (HTG) 5 2025-12-08
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi… Ended

2024-519945-31-00 Type 1 Diabetes 5 2025-08-21
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Severe hypertriglyceridemia (SHTG) 5 2024-10-31
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended

2023-506962-30-00 Non-alcoholic steatohepatitis (NASH) 5 2021-03-29
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With… Ended

2023-507280-18-00 Type 2 Diabetes 5 2024-02-23
A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended

2023-503657-35-00 Obesity 5 2023-10-10
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24